OBJECTIVES: In this study, we analyzed the prognostic value of different MRI progression patterns for survival in patients with recurrent malignant glioma treated with the vascular endothelial growth factor antibody bevacizumab. PATIENTS AND METHODS: Twenty-six adult patients with recurrent malignant glioma treated with bevacizumab or bevacizumab/irinotecan were retrospectively analyzed for the development of contrast-enhanced (T1-weighted MRI) and T2/FLAIR lesions. According to the progression pattern, patients were divided into 3 subgroups: (1) patients with primarily progressive contrast-enhanced lesions in the first MRI after initiation of therapy ('primary PD group'); (2) patients with stable or regressive enhanced lesions but progressive FLAIR lesions ('FLAIR-only PD group'), and (3) patients with stable or regressive contrast-enhanced T1 and FLAIR lesions ('no PD group'). RESULTS: Overall survival (OS) in the 6 patients in the FLAIR-only PD group was not significantly different from the 11 patients in the no PD group (median 311 vs. 254 days, respectively). In contrast, survival in the FLAIR-only PD group was significantly better (p = 0.025) than in the primary PD group. CONCLUSION: FLAIR-only progression is not an independent prognostic factor negatively influencing OS in recurrent glioblastoma treated with bevacizumab and should not lead to discontinuation of bevacizumab therapy.
OBJECTIVES: In this study, we analyzed the prognostic value of different MRI progression patterns for survival in patients with recurrent malignant glioma treated with the vascular endothelial growth factor antibody bevacizumab. PATIENTS AND METHODS: Twenty-six adult patients with recurrent malignant glioma treated with bevacizumab or bevacizumab/irinotecan were retrospectively analyzed for the development of contrast-enhanced (T1-weighted MRI) and T2/FLAIR lesions. According to the progression pattern, patients were divided into 3 subgroups: (1) patients with primarily progressive contrast-enhanced lesions in the first MRI after initiation of therapy ('primary PD group'); (2) patients with stable or regressive enhanced lesions but progressive FLAIR lesions ('FLAIR-only PD group'), and (3) patients with stable or regressive contrast-enhanced T1 and FLAIR lesions ('no PD group'). RESULTS: Overall survival (OS) in the 6 patients in the FLAIR-only PD group was not significantly different from the 11 patients in the no PD group (median 311 vs. 254 days, respectively). In contrast, survival in the FLAIR-only PD group was significantly better (p = 0.025) than in the primary PD group. CONCLUSION: FLAIR-only progression is not an independent prognostic factor negatively influencing OS in recurrent glioblastoma treated with bevacizumab and should not lead to discontinuation of bevacizumab therapy.
Authors: Elizabeth R Gerstner; Xiaobu Ye; Dan G Duda; Michael A Levine; Tom Mikkelsen; Thomas J Kaley; Jeffrey J Olson; Burt L Nabors; Manmeet S Ahluwalia; Patrick Y Wen; Rakesh K Jain; Tracy T Batchelor; Stuart Grossman Journal: Neuro Oncol Date: 2015-05-24 Impact factor: 12.300
Authors: Christina Schaub; Sied Kebir; Nina Junold; Elke Hattingen; Niklas Schäfer; Joachim P Steinbach; Astrid Weyerbrock; Peter Hau; Roland Goldbrunner; Michael Niessen; Frederic Mack; Moritz Stuplich; Theophilos Tzaridis; Oliver Bähr; Rolf-Dieter Kortmann; Uwe Schlegel; Friederike Schmidt-Graf; Veit Rohde; Christian Braun; Mathias Hänel; Michael Sabel; Rüdiger Gerlach; Dietmar Krex; Claus Belka; Hartmut Vatter; Martin Proescholdt; Ulrich Herrlinger; Martin Glas Journal: J Cancer Res Clin Oncol Date: 2018-05-28 Impact factor: 4.553
Authors: Renske Gahrmann; Martin van den Bent; Bronno van der Holt; René Michel Vernhout; Walter Taal; Maaike Vos; Jan Cees de Groot; Laurens Victor Beerepoot; Jan Buter; Zwenneke Hendrieke Flach; Monique Hanse; Bas Jasperse; Marion Smits Journal: Neuro Oncol Date: 2017-06-01 Impact factor: 12.300